![](https://brenus-pharma.com/wp-content/uploads/2024/02/cell-left.png)
![](https://brenus-pharma.com/wp-content/uploads/2024/02/cell-right.png)
![](https://brenus-pharma.com/wp-content/uploads/2024/02/cell-right.png)
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens